IMMUTEP Ltd (IMMP) Form 6-K — Jun 4, 2026
Immutep announced positive interim Phase I data for its first-in-class LAG-3 agonist antibody, IMP761, to be presented at the EULAR 2026 Congress. The first-in-human study met its primary endpoint, demonstrating favorable safety and tolerability in healthy volunteers across dose levels from 0.9 mg/kg to 7 mg/kg. The data showed statistically significant pharmacodynamic activity at the 7 mg/kg dose, including reduced local inflammatory responses and attenuated T-cell activity compared to placebo (p=0.029). These results support the potential of IMP761 to treat autoimmune diseases driven by T-cell-mediated inflammation and justify further clinical evaluation in a Phase II setting.
Key figures
- P value
- 0.029
- Dosing frequency
- once per 4-week
- Dose levels tested
- 0.9 mg/kg to 7 mg/kg
- Statistically significant dose
- 7 mg/kg
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.